FDA grants Lilly's olomorasib breakthrough therapy status for pancreatic cancer
Go back to FDA grants Lilly's olomorasib breakthrough therapy status for pancreatic cancer| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1226.11 -5.83 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 283.82 | |||
| Day Low | $1210.01 | EPS | $4.32 | |||
| Volume | 690,341 | |||||
